Why Nuvectis Pharma, Inc.’s (NVCT) Stock Is Down 5.14%
As of Tuesday, September 08, Nuvectis Pharma, Inc.’s NVCT share price has dipped by 5.14%, which has investors questioning if this is right time to buy.Michael Rose
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
Nuvectis Pharma, Inc., a clinical-stage biopharmaceutical company, focuses on the development of precision medicines for the treatment of serious conditions of unmet medical need in oncology. The company is developing NXP900, a small molecule drug candidate, which is in Phase 1b clinical trial that inhibits the proto-oncogene c-Src and YES1 kinases for treating solid tumors. The company was formerly known as Centry Pharma, Inc. and changed its name to Nuvectis Pharma, Inc. in July 2021. Nuvectis Pharma, Inc. was incorporated in 2020 and is based in Fort Lee, New Jersey.
Commentary & Analysis
Why Nuvectis Pharma, Inc.’s (NVCT) Stock Is Down 5.43%
As of Wednesday, August 26, Nuvectis Pharma, Inc.’s NVCT share price has dipped by 5.43%, which has investors questioning if this is right time to buy.Jenna Brashear
Why Nuvectis Pharma, Inc.’s (NVCT) Stock Is Up 6.31%
As of Wednesday, August 19, Nuvectis Pharma, Inc.’s NVCT share price has surged by 6.31%, which has investors questioning if this is right time to sell.Jenna Brashear
Why Nuvectis Pharma, Inc.’s (NVCT) Stock Is Up 5.87%
As of Tuesday, August 18, Nuvectis Pharma, Inc.’s NVCT share price has surged by 5.87%, which has investors questioning if this is right time to sell.Cynthia McLaughlin
Why Nuvectis Pharma, Inc.’s (NVCT) Stock Is Down 7.08%
As of Tuesday, August 04, Nuvectis Pharma, Inc.’s NVCT share price has dipped by 7.08%, which has investors questioning if this is right time to buy.Jenna Brashear
Financial Summary
| Share Statistics | NVCT | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $783.3 | $269.3 | 42% |
|
| Shares Out (Mil) | 23.5 | 54.0 | 33% |
|
| Institutional Ownership | 49.0% | 93.0% | 23% |
|
| Float (Mil) | 21.2 | 42.2 | 30% |
|
| Beta | -0.26 | 0.95 | 3% |
|
| Avg Daily Volume (000s) | 158 | 473 | 42% |
|
| Price Change (52-week) |
282.8% | 55.9% | 99% |
|
| Growth | NVCT | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | na | 14.1% | na |
|
| Net Income (5yr) | na | (10.1%) | na |
|
| EPS (5yr) | na | 15.7% | na |
|
| Dividends (5yr) | na | 0.0% | na |
|
| Cash Flow (5yr) | na | (15.6%) | na |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | na | na | na | |
| Current EPS | na | na | na | |
| Month Ago EPS | na | na | na | |
| # Rev Up | na | na | na | |
| # Rev Down | na | na | na | |
| Three Months Ago EPS | na | na | na | |
| Year/Year Chg | na | na | na | |
| Financials | NVCT | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | na | $37 | na |
|
| Net Income (TTM) (Mil) | ($28) | ($43) | 21% |
|
| EPS (TTM) | ($1.305) | ($1.500) | 19% |
|
| Operating Cash Flow (TTM) (Mil) | ($20) | ($31) | 15% |
|
| Net Cash Flow (TTM) (Mil) | na | $2 | na |
|
| Long-Term Debt (Q1) (Mil) | $0 | $4 | 0% |
|
| Enterprise Value (Q1) (Mil) | $605 | $182 | 36% |
|
| Valuation | NVCT | Industry Median |
Percentile (All Stocks) |
|
| P/B | 70.71 | 2.62 | 99% |
|
| P/E | na | 19.4 | na |
|
| Dividend Yield | na | 0.0% | na |
|
| PEG (5yr hist) | na | 1.0 | na |
|
| Ratios | NVCT | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | na | 67.6% | na |
|
| Net Margin | na | (73.5%) | na |
|
| ROA | (112.8%) | (47.9%) | 5% |
|
| ROE | (214.6%) | (55.0%) | 4% |
|
| Liabilities to Assets | 59.4% | 29.5% | 53% |
|
| F-Score | 1 | 3 | 1% |
|
Nuvectis Pharma, Inc. did not pass any screens on 9/11/2026.
